Biotech · Private company · South San Francisco, CA, US
Kezar Life Sciences, Inc.
SEC CIK 0001645666
Track this companyFree. Adds Kezar Life Sciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- KZR-616Phase 2 · PolymyositisClinicalTrials.gov · fetched Nov 12, 2026
- KZR-616Phase 2 · Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- KZR-616Phase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- zetomipzomibPhase 2 · Autoimmune HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- zetomipzomibPhase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- zetomipzomib in open-label extensionPhase 2 · Autoimmune HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- KZR-261Phase 1 · Advanced/Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)PHASE2 · TERMINATED · started Nov 3, 2023ClinicalTrials.gov NCT05781750 · fetched Nov 12, 2026
- A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)PHASE2 · COMPLETED · started May 23, 2023ClinicalTrials.gov NCT05569759 · fetched Nov 12, 2026
- KZR-261 in Subjects With Advanced Solid MalignanciesPHASE1 · TERMINATED · started Sep 30, 2021ClinicalTrials.gov NCT05047536 · fetched Nov 12, 2026
- Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.PHASE2 · COMPLETED · started Nov 4, 2020ClinicalTrials.gov NCT04628936 · fetched Nov 12, 2026
- A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITPPHASE2 · WITHDRAWN · started Jul 1, 2020ClinicalTrials.gov NCT04039477 · fetched Nov 12, 2026
- A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or DermatomyositisPHASE2 · COMPLETED · started Jan 14, 2020ClinicalTrials.gov NCT04033926 · fetched Nov 12, 2026
- A Study of KZR-616 in Patients With SLE With and Without Lupus NephritisPHASE1_PHASE2 · COMPLETED · started Feb 20, 2018ClinicalTrials.gov NCT03393013 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 7, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 22, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 16, 2025 · fetched Nov 12, 2026